Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 1 2Phase 4 1Phase 3 1

Status

Completed 6Recruiting 5Terminated 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Ovarian Neoplasms 1Metastatic Solid Tumors 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9venetoclax 7toripalimab 7pembrolizumab 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7irinotecan sucrosofate 6Temozolomide 6Fluorouracil 6tislelizumab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5HMPL-013 5Etoposide 5Dexamethasone 5Cisplatin 5Carboplatin 5Capecitabine 5Biopsy 5sintilimab 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Platinum × Clear all
NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07272590 2025-12-09

Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
290 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡